Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173


Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II.

J Infect Dis. 2005 Apr 15;191(8):1350-60.


Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer.

Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP.

Clin Infect Dis. 2005 Jul 1;41(1):60-6.


Zygomycosis: the re-emerging fungal infection.

Chayakulkeeree M, Ghannoum MA, Perfect JR.

Eur J Clin Microbiol Infect Dis. 2006 Apr;25(4):215-29. Review.


Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.


Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.

Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP.

Pharmacotherapy. 2007 Dec;27(12):1644-50.


Ten years' experience in zygomycosis at a tertiary care centre in India.

Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, Sakhuja V.

J Infect. 2001 May;42(4):261-6.


[Zygomycetes and zygomycosis in the new era of antifungal therapies].

Torres-Narbona M, Guinea J, Muñoz P, Bouza E.

Rev Esp Quimioter. 2007 Dec;20(4):375-86. Review. Spanish.


Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome.

Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Muñoz P, Patel R, Fortun J, Martin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, Blumberg E, Julia MB, Humar A, Houston S, Lass-Flörl C, Johnson L, Dubberke ER, Barron MA, Lortholary O.

J Infect Dis. 2009 Sep 15;200(6):1002-11. doi: 10.1086/605445.


Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Chamilos G, Lewis RE, Kontoyiannis DP.

Clin Infect Dis. 2008 Aug 15;47(4):503-9. doi: 10.1086/590004.


Forty-one recent cases of invasive zygomycosis from a global clinical registry.

Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild JJ, Cornely OA.

J Antimicrob Chemother. 2010 Feb;65(2):296-302. doi: 10.1093/jac/dkp430.


Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K.

Clin Infect Dis. 2009 Feb 1;48(3):265-73. doi: 10.1086/595846. Erratum in: Clin Infect Dis. 2009 Mar 1;48(5):690.


Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.

Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, Diekema DJ, Pfaller MA.

Clin Infect Dis. 2004 Aug 15;39(4):584-7.


Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.

Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP.

J Infect Dis. 2009 May 1;199(9):1399-406. doi: 10.1086/597615.


Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.

Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, Revankar SG.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):443-6. doi: 10.1016/j.diagmicrobio.2008.08.003.


Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.

Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D.

Br J Haematol. 2005 Oct;131(2):201-7.


Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.

Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.

Diagn Microbiol Infect Dis. 2005 May;52(1):15-20.


Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.

Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, de Gaetano Donati K, Fadda G, Cauda R, Posteraro B.

J Antimicrob Chemother. 2008 Dec;62(6):1379-85. doi: 10.1093/jac/dkn381.


Invasive zygomycosis in India: experience in a tertiary care hospital.

Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, Varma SC, Singhi S, Bhansali A, Sakhuja V.

Postgrad Med J. 2009 Nov;85(1009):573-81. doi: 10.1136/pgmj.2008.076463.


A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.

Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, Gorelik A, Dally N, Zuckerman T, Haddad N, Fineman R, Dann EJ.

Bone Marrow Transplant. 2006 Jul;38(2):127-34.


Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA.

Clin Infect Dis. 2004 Sep 1;39(5):743-6.

Items per page

Supplemental Content

Support Center